Literature DB >> 10496908

Expression of herpes simplex virus thymidine kinase in Toxoplasma gondii attenuates tachyzoite virulence in mice.

J R Radke1, M W White.   

Abstract

We tested the virulence in mice of Toxoplasma gondii RH strain tachyzoites containing various copies of the chloramphenicol acetyl transferase-herpes simplex virus thymidine kinase fusion sequence (CAT-HSTK). Tachyzoite isolates containing >/=five copies of the fusion sequence were not lethal to female CD-1 outbred or BALB/c inbred mice, at doses up to 10(6) parasites, while the parental RH strain caused 100% mortality within 2 weeks at doses as low as 10 parasites. Mice infected with CTK11, an isolate containing five copies of the fusion sequence, showed no overt symptoms of disease and were protected from lethal challenge with the parental RH strain. The CTK11 isolate showed no difference in growth rate, the rate of host cell invasion, or extracellular viability in cell culture compared with parental RH parasites, demonstrating that the CAT-HSTK fusion protein does not affect the normal viability of this isolate. B11, B11C, and D1 isolates contained one or two copies of the CAT-HSTK coding sequence, were not sensitive to thymidine in cell culture, and caused 100% mortality in CD-1 outbred mice in <12 days. A fourth isolate, D1C, contained seven copies of the CAT-HSTK fusion sequence and was sensitive to exogenous thymidine (50% inhibitory concentration = 5.5 microM). Mice infected with D1C showed no symptoms of disease and survived beyond 90 days, thus correlating increased CAT-HSTK gene copies with thymidine sensitivity in cell culture and attenuated virulence in mice. BALB/c mice containing a targeted disruption of the gamma interferon gene (gko) were also susceptible to infection with CTK11 parasites but could be rescued by administration of subcutaneous thymidine once each day for 5 or 10 days following infection. These results suggest that the attenuation of CAT-HSTK(+) isolates in mice is directly due to active thymidine kinase that likely alters the pyrimidine biosynthetic pathway in these parasites.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496908      PMCID: PMC96883          DOI: 10.1128/IAI.67.10.5292-5297.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Toxoplasmosis: the nature of virulence.

Authors:  H E KAUFMAN; J S REMINGTON; L JACOBS
Journal:  Am J Ophthalmol       Date:  1958-11       Impact factor: 5.258

2.  Synchronization of the human promyelocytic cell line HL 60 by thymidine.

Authors:  B T Mortensen; N R Hartmann; I J Christensen; J K Larsen; T Kristensen; S B Wieslander; N I Nissen
Journal:  Cell Tissue Kinet       Date:  1986-05

3.  An overview of the problem of toxoplasmosis and pneumocystosis in AIDS in the USA: implication for future therapeutic trials.

Authors:  B J Luft; K G Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

4.  Evaluation of the safety and efficacy of vaccination of nursing pigs with living tachyzoites of two strains of Toxoplasma gondii.

Authors:  R D Pinckney; D S Lindsay; B L Blagburn; T R Boosinger; S A McLaughlin; J P Dubey
Journal:  J Parasitol       Date:  1994-06       Impact factor: 1.276

5.  Reduced replication of Toxoplasma gondii is necessary for induction of bradyzoite-specific antigens: a possible role for nitric oxide in triggering stage conversion.

Authors:  W Bohne; J Heesemann; U Gross
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Live and killed vaccines against toxoplasmosis in mice.

Authors:  H Waldeland; J K Frenkel
Journal:  J Parasitol       Date:  1983-02       Impact factor: 1.276

7.  Deoxyribonucleoside triphosphate metabolism and the mammalian cell cycle. Effects of thymidine on wild-type and dCMP deaminase-deficient mouse S49 T-lymphoma cells.

Authors:  S Eriksson; S Skog; B Tribukait; K Jäderberg
Journal:  Exp Cell Res       Date:  1984-11       Impact factor: 3.905

8.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome.

Authors:  B J Luft; R G Brooks; F K Conley; R E McCabe; J S Remington
Journal:  JAMA       Date:  1984-08-17       Impact factor: 56.272

10.  Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant.

Authors:  D Buxton; K Thomson; S Maley; S Wright; H J Bos
Journal:  Vet Rec       Date:  1991-08-03       Impact factor: 2.695

View more
  3 in total

1.  Phenotypic and gene expression changes among clonal type I strains of Toxoplasma gondii.

Authors:  Asis Khan; Michael S Behnke; Ildiko R Dunay; Michael W White; L David Sibley
Journal:  Eukaryot Cell       Date:  2009-10-02

2.  Toxoplasma gondii: Laboratory Maintenance and Growth.

Authors:  Asis Khan; Michael E Grigg
Journal:  Curr Protoc Microbiol       Date:  2017-02-06

3.  N-terminal palmitoylation is required for Toxoplasma gondii HSP20 inner membrane complex localization.

Authors:  M G De Napoli; N de Miguel; M Lebrun; S N J Moreno; S O Angel; M M Corvi
Journal:  Biochim Biophys Acta       Date:  2013-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.